Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers formulations in various therapeutic areas, including central nervous system, dermatology, cardiology, oncology, neuropsychiatry, gastroenterology, anti-infectives, diabetology, pain/analgesics, vitamins/minerals/nutrients, respiratory, gynaecology, urology, ophthalmology, orthopaedic, nephrology, dental, and other areas. It provides APIs for anti-cancers, peptides, steroids, hormones, and immunosuppressant drugs. In addition, the company offers generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; speciality medications, and antiretrovirals medications, as well as over-the-counter products. The company was founded in 1983 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for SUNPHARMA
Revenue projections for SUNPHARMA

Sun Pharmaceutical Industries Limited's revenue projections show a decrease from last year, which tends to make investors more cautious. This could have a negative impact on the company's bottom line, as lower revenues typically suggest reduced profitability and growth potential, prompting concern among investors.

Financial Ratios:

currentRatio 2.570000
forwardPE 29.042746
debtToEquity 6.675000
earningsGrowth 0.024000
revenueGrowth 0.089000
grossMargins 0.781920
operatingMargins 0.232560
trailingEps 43.570000
forwardEps 56.189590

SUNPHARMA's current ratio of 2.57 highlights the company's solid liquidity, indicating that it can easily service its short-term debt. SUNPHARMA's ample cash reserves and current assets ensure that the company is well-positioned to meet its immediate financial liabilities.
Sun Pharmaceutical Industries Limited's Forward PE being in a reasonable range suggests the stock is fairly priced based on its earnings. The stock isn't overpriced, leaving room for growth, making it an attractive investment for those seeking opportunities for future value appreciation.
Sun Pharmaceutical Industries Limited's positive gross and operating margins indicate a profitable and efficient business model. These metrics highlight the company's ability to generate income while controlling operational costs, reflecting strong financial performance.
SUNPHARMA's forward EPS surpassing its trailing EPS signals projected growth in profitability, with the company expected to perform better this year. This forecast suggests that SUNPHARMA's earnings will improve compared to the previous financial year, highlighting optimism in its financial outlook.

Price projections:

Price projections for SUNPHARMA
Price projections for SUNPHARMA

Sun Pharmaceutical Industries Limited's stock price has consistently been near the lower edge of expected values, indicating potential struggles in meeting growth projections. This trend may reflect a cautious market sentiment toward the company.

Recommendation changes over time:

Recommendations trend for SUNPHARMA
Recommendations trend for SUNPHARMA


Analysts' recent buy bias toward SUNPHARMA suggests the stock is gaining favor as a strong investment choice. This optimism could drive more investors to see SUNPHARMA as a smart place to invest, further bolstering confidence in the company's long-term growth and potential returns.